Abstract
Manipulating fungal genomes is an important tool to understand the function of target genes, pathobiology of fungal infections, virulence potential, and pathogenicity of medically important fungi, and to develop novel diagnostics and therapeutic targets. Here, we provide an overview of recent advances in genetic manipulation techniques used in the field of medical mycology. Fungi use several strategies to cope with stress and adapt themselves against environmental effectors. For instance, mutations in the 14 alpha-demethylase gene may result in azole resistance in Aspergillus fumigatus strains and shield them against fungicide’s effects. Over the past few decades, several genome editing methods have been introduced for genetic manipulations in pathogenic fungi. Application of restriction enzymes to target and cut a double-stranded DNA in a pre-defined sequence was the first technique used for cloning in Aspergillus and Candida. Genome editing technologies, including zinc-finger nucleases (ZFNs) and transcriptional activator-like effector nucleases (TALENs), have been also used to engineer a double-stranded DNA molecule. As a result, TALENs were considered more practical to identify single nucleotide polymorphisms. Recently, Class 2 type II Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 technology has emerged as a more useful tool for genome manipulation in fungal research.
Keywords: gene editing techniques, CRISPR/Cas9, medically important fungi
1. Introduction
The fungi represent a large, diverse group of eukaryotic microorganisms that have a small genome size, short timeframes for growth and reproduction, and share homologous genes with humans [1]. Aspergillus, Candida, and Cryptococcus are the major fungal genera that cause opportunistic and life-threatening mycoses [2,3]. Over the past decades, genetic engineering has paved the way for the desired modifications by gene manipulation using a wide range of methods [4,5]. Genetic tools have been widely used to understand the virulence potential and pathobiology of fungal infections [6], as well as patterns of resistance development against antifungals [7]. Genome editing is a very useful tool which allows manipulation of a target site in a shorter period of time [8,9]. Here, we discuss the recent advances in genetic manipulation techniques that have been used in the field of medical mycology research with special emphasis on CRISPR/Cas9 technology. Additionally, we address the future perspectives of CRISPR/Cas9 applications in medically relevant fungi.
2. Genome Editing Technologies
Genome editingtechnology is a flexible engineering tool for genetic manipulation of microorganisms including fungi [8,9].
2.1. RNA Interference (RNAi)
RNA interference (RNAi) is an RNA-mediated, sequence specific gene silencing mechanism involved in multiple biological processes, particularly in host defense and gene regulation [10,11]. RNAi is initiated by a RNAse III enzyme (Dicer) that cleaves a long double-stranded RNA (dsRNA) into double stranded ~21–24 nucleotides small interfering RNAs (siRNAs). Each siRNA consists of a guide strand and passenger strand. As guide strand becomes part of an active RNA-induced silencing complex (RISC), the passenger strand is degraded by the following cellular events in the cytoplasm. The guide strand of the siRNA–RISC complex base-pairs with the complementary mRNA target sequences and initiates endonucleolytic cleavage by induced Argonaute protein (AGO; catalytic component of the RISC complex), which prevents translation of the target transcript (Figure 1). Different components of the fungal RNAi machinery not only play key roles in fungal growth and development, but also important in pathogenesis. In designing a single siRNA or an RNAi hairpin construct capable of producing a number of siRNAs specific for the target gene, it is important that the siRNA(s) targeting the mRNA must have a high efficiency of silencing as well as a low probability of binding to off-target mRNAs.
Impact of RNAi on the cyp51A gene in the itraconazole-resistant Aspergillus fumigatus has shown that in addition to reducing the expression of the cyp51A gene, the minimum inhibitory concentration (MIC) of itraconazole has also decreased [12]. Previous studies showed that the deletion of ERG3 and ERG11 genes in C. albicans isolates induced increased azole sensitivity [13,14]. Moreover, deletion of these genes impaired the invasion of C. albicans into the oral mucosa [15]. Epigenetic pathways establish drug resistance in fungi by affecting a number of chromatin or RNA modifications. The changes caused by RNA are induced through small RNAs (sRNAs) and RNAi. A type of genetic mutation that contributes to resistance to rapamycin and FK506 has also been identified in Mucor circinelloides through RNAi pathway. Histone acetylation also activates the epigenetic machinery of chromatin. The acetylation process, which influences the nature of histone, has been shown to be one of the mechanisms of drug resistance in C. albicans [16,17]. Histone deacetylation-induced chromatin alteration was revealed as a function of HDAC genes which directly affects the virulence of the microorganism [18,19]. RNAi has been used as an important reverse genetics approach to understand gene function in fungi. It is inexpensive and enables us to carry out high-throughput interrogation of gene function [20,21]. However, one of the major disadvantages of RNAi is that it provides only temporary inhibition of gene function and unpredictable off-target effects [22].
2.2. Restriction Enzymes
Restriction enzymes are among the first generation of genome editing tools used in the field of medical mycology. These enzymes are designed to induce genome changes by cutting DNA molecules at defined points and inserting new genes at the cutting sites [23]. This mechanism of action of the restriction enzymes has made them a valuable method for cloning. However, the major issue with this method is that it is not easy to specify in advance where exactly the gene will be inserted, as the recognition sequences of most restriction enzymes are just a few base pairs long and often repeat several times in a genome. Moreover, the specificity of a restriction enzyme is dependent on environmental conditions. Since the discovery of restriction enzymes in the early 1970s, they have been widely used for the genetic manipulation of medically important fungi. Restriction enzyme mediated integration (REMI) has been employed to create mutants in medically relevant fungi including C. albicans, A. nidulans, and A. fumigatus [24,25]. However, it is important to note that in C. albicans, only heterozygous mutations are obtained. Aspergillus and Candida spp. are best examples of pathogenic fungi in which azole resistance mechanisms have been explored using the ability of restriction enzymes to provide a series of genetic patterns [26,27,28].
2.3. Zinc-Finger Nucleases (ZFNs)
Due to the mentioned limitations regarding restriction enzymes, scientists looked for ways of improving the precision of these enzymes and altering them so that they could distinguish a unique sequence in the genome. Zinc finger nucleases are examples of such unique sequences [29].
The efficiency of ZFNs as a gene editing tool is much more advanced than that of restriction enzymes. ZFN monomers are molecular proteins with two functional fused domains including the C2H2 zinc-finger (ZF) DNA-binding domain, which targets three base pairs and a non-specific catalytic domain of the FokI endonuclease. The C2H2 ZF domain is consisting of about 30 amino acids, two antiparallel β-sheets and an α-helix, and a zinc ion coordinated by two cysteine residues in the β-sheets and two histidine residues in the α-helix. FokI is a type IIS restriction enzyme involved in cleaving DNA at a distinct distance away from their recognition sites. To generate three-finger ZFs recognizing a 9-bp sequence in modular assembly, the user joins the appropriate ZF modules together. A DNA double-stranded cleavage requires dimerization of two FokI nuclease domains [30,31]. Although ZFN method was applied to gene editing in human cells and model organisms including Arabidopsis thaliana, Caenorhabditis elegans, and Drosophila, there have not been any studies done in fungi.
2.4. Transcription Activator-Like Effector Nucleases (TALENs)
TALENs have emerged as an alternative genome editing tool to ZFNs and are similar to ZFNs in that they can cleave their double-stranded DNA target at any desired site. Fok1 nuclease is a common functional part between ZFNs and TALENs. However, designing TALENs is more straightforward than ZNFs. In TALEN-mediated gene editing process, TALEs bind their DNA at the desired site by arrays of highly conserved 33–35 amino acid repeats that are flanked by additional TALE-derived domains at the amino-terminal and carboxy-terminal ends of the array. Each TALE repeat is largely identical, except for two highly variable residues typically found at positions 12 and 13 of the domain, referred to as the repeat variable di-residues (RVDs). This structural difference has increased the detection coefficient in TALENs and has shown higher target binding specificity as compared to ZFNs. Thus, TALENs have the ability to identify single nucleotide polymorphisms (SNPs) [32,33].
2.5. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR Associated Protein 9 (CRISPR-Cas9)
The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/CRISPR-associated protein 9 (Cas9) is an adaptive immunity system in bacteria and was initially used for genome editing in mammalian and yeast cells [34,35,36]. Gradually it has become a revolutionary tool in molecular biology and biotechnology that enables us to perform precise genomic, epigenomic, RNA editing, gene expression regulation, nucleic acid detection, and several applications in a wide variety of organisms [36,37,38,39,40,41,42,43,44]. Currently, delivery of the CRISPR system’s components into fungal cells through different types of vectors and assembled purified sgRNA/Cas9 complexes have enabled us to mutate the genome or alter gene expression regulation in dozens of fungal species [36,45,46,47,48]. Alternatively, cell-penetrating peptides have been shown to be able to enter into Candida spp. [49,50]. These CRISPR-empowered enhancements have been considered a scientific breakthrough in fungal molecular biology and biotechnology [51], and stem from its versatile potential to functional characterization and breeding of clinically and industrially important fungi.
3. Mechanism of Action of CRISPR-Cas9
The type II CRISPR-Cas system (CRISPR-Cas9 from Streptococcus pyogenes) consists of two key molecules, including the Cas9 DNA endonuclease and a small chimeric protospacer adjacent motif (PAM)—dependent guide RNA (sgRNA). The sgRNA is composed of CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) [45], The Cas operon encodes Cas1, Cas2, and Cas9 signature proteins, and sometimes a fourth protein (Csn2 or Cas4). Moreover, repeat-spacer array alternatively contains repeats and unique spacers [52,53]. The CRISPR-array initially transcribes a precursor-CRISPR RNA (pre-crRNA), which is then processed and matured by trans-activating crRNA (tracrRNA) and RNaseIII. TracrRNA is a partial complement to a repeating sequence of crRNA, forming the chimeric sgRNA, which subsequently directs the Cas9 protein to the cleavage site. The spacer sequence of crRNA is also complementary to target DNA, such as viral nucleic acids. Then, the multifunctional and multidomain protein, Cas9, in complex with 20-nucleotide (nt) of sgRNA, cleaves both strands of target DNA preceding to protospacer adjacent motif (PAM) [54,55]. The native PAM sequence used by Cas9 is 5′NGG 3′, followed by a downstream crRNA complementary sequence that is crucial for discrimination of host and foreign nucleic acid [55,56]. The cleavage of target strand hybridizing to guide RNA and non-target strand is performed by HNH and RUVC domains of this endonuclease, respectively. Then, this fragment integrates in the CRISPR locus, allowing it to act as a new spacer sequence. Cells can detect and clear invading DNA during subsequent infection of the similar invader. This system can be effectively programmed by modifying the sequence of sgRNA to trigger desired nucleic acid cleavage. Nuclease-induced double strand breaks can be repaired by either error-prone non-homologous end joining (NHEJ) or homology directed repair (HDR) [56]. The high-fidelity HDR pathway serves as a precise gene modification by homologous recombination between donor template and repair DNA, whereas the latter leads to variable nucleotides insertion or deletion, eventually results in several mutations [56]. Figure 2 shows the schematic representation of RNA-guided Cas9 constructs designed for genome editing.
4. Applications of CRISPR-Cas9 Genome Editing Tool in Medically Important Fungi
4.1. Clinically Relevant Yeasts
Candida spp. are challenging for the molecular geneticist; the genome engineering and drug development against Candidiasis has been difficult for several years. Vyas and colleagues were the first to develop the CRISPR/Cas9 system in C. albicans [57]. Using this system, homozygous gene knock-out and multiple gene mutation have been successfully created in this fungus. Efforts to improve CRISPR-mediated genome editing have been developed in other Candida spp. Recently, Nguyen and colleagues reported a rapid and efficient edition without performing a molecular cloning step and utilizing permanent markers in the engineering location [58].
Since then, the CRISPR system has been utilized in several Candida spp. [59,60,61,62,63,64,65,66,67,68]. Therefore, CRISPR-based single and multiple gene knock-out libraries would be possible in these fungi, which further help us to develop new antifungal drugs. Cryptococcosis is a life-threatening fungal disease caused by Cryptococcus neoformans and Cryptococcus gattii. Cryptotoccocus spp. are found in soils contaminated with bird droppings, and in association with rotting vegetation, including eucalyptus tree hollows [69]. The prevalence of Cryptococcosis has been increasing over the past years for many reasons, including worldwide prevalence of AIDS and the expanded use of immunosuppressive drugs. Although the most common presentation of Cryptococcosis is of C. neoformans infection in immunocompromised people, C. gattii is being increasingly recognized as a pathogen in immunocompetent hosts [70]. There is an urgent need to use the CRISPR system in Cryptococcus spp. because low rates of homologous integration have hindered molecular genetic studies in these fungi. This limitation has been a major obstacle for the diagnosis and treatment of deadly Cryptococcal disease. Recently, the CRISPR/Cas9 system has been developed to stimulate homologous recombination (HR) for gene alteration in C. neoformans [71,72,73,74,75,76]. Taken together, CRISPR constructs can be successfully used for gene editing in Cryptococcus spp. and thus the CRISPR system would be a promising tool for drug discovery against Cryptococcosis. Strategies and applications of the CRISPR/Cas system in medically important yeasts are shown in Table 1.
Table 1.
Organism | CAS9 Expression Module | GRNA Expression Module | Target Gene (S) | Purpose of Application | Editing Rate and Result | References |
---|---|---|---|---|---|---|
C. albicans | Candida/Saccharomyces codon–optimized version of Cas9 (CaCas9)/the ENO1 promoter | The RNA polymerase III (Pol III) promoter SNR52 | ADE2, CDR1/CDR2 | To generate homozygous mutations in one transformation by Duet and Solo system | Duet system showed 20–40% mutagenesis efficiency, and Solo system enabled 60–80% targeting | Vyas et al. (2015) [57] |
C. albicans | Transient CRISPR-Cas9 system by using a SAT1-FLP system | SNR52P/TENO1 | NDT80, REP1, and RON1 | To better understand role of target genes (single or in combination) in virulence | Single, double, and triple deletion strains were successfully constructed | Min et al. (2018) [60] |
C. albicans | US-pENO1 ˃ Cas9-NAT | NAT-pSNR52-gRNA-DS | ADE2, URA3, WOR1,WOR, and CZF1 | To develop a marker less system without need for molecular cloning step | 80% single gene deletion, 20% double genes deletion and ˃50% integration efficiency | Nguyen et al. (2017) [58] |
C. albicans | CIp-ARG4-PTEF CaCAS9 | PADH1-tRNA-driven gRNA expression | RFP | To optimize gRNA intracellular expression | Increase the gene editing efficiency by 10-fold | Ng et al. (2017) [64] |
C. albicans | CaCas9 into the C. albicans genome at the NEUT5L locus | 5′ homology arm–SNR52 promoter–gRNA1–gRNA2-3′ homology arm | antifungal efflux and biofilm adhesion factors | To develop a gene drive array system for the generation of combinatorial deletion mutants | Two larges pairwise gene deletion mutants were successfully generated | Shapiro et al. (2018) [63] |
C. albicans | the ENO1 promoter/Cas9 (CaCas9)/TCYC1 | SNR52P/TENO1 | ADE2 | To describe a transient CRISPR-Cas9 system for efficient gene deletion | Homozygous deletions by introduction of CaCas9 transiently | Min et al. (2016) [59] |
C. parapsilosis | TEF1p-CAS9-TEF1t | pCpSNR52-sgRNA-SUP4t and cpGAPDHp-HH-sgRNA-HDV-GAPDHt | ADE2, CPAR2_101060 and URA3 | To apply gene manipulation in single transformation step which can be used for editing of any number of target genes | The system yielded up to 100% efficiency across a panel of 20 clinical isolates | Lombardi et al. (2017) [66] |
C. glabrata | pTEF1-Cas9-tCYC1/pCYC1-Cas9-tCYC1 | pSNR52-sgRNA-tTY2/pRNAH1-sgRNA-tTY2 | ADE2, VPK1 and YPS11 | To establish a loss-of-function mutation through the NHEJ repair pathway | High | Enkler et al. (2016) [61] |
C. glabrata | pTEF-Cas9-KanMX | pSNR52-sgRNA-CYC1t | ADE2, MET15 and SOK2 | To compare genome modifications in C. glabrata wild type and lig4 strains | Targeting efficiency in the lig4Δ mutant was higher than in the wild type strain | Cen et al. (2017) [62] |
C. albicans | Codon-optimized version of Cas9(CaCas9)-SV40NLS | SNR52 RNA polymerase III promoter | CDR1 and CDR2 | To present a modified gene-drive-based assay for gene manipulation | − | Halder et al. (2019) [65] |
C. albicans | ACT1p-dCAS9-ACT1t | SNR52p-gRNA tail | ADE2 | To demonstrate a functional CRISPRi system for transcriptional repression | 20-fold repression of target gene achieved | Wensing et al. (2019) [68] |
C. parapsilosis, C. orthopsilosis, C. metapsilosis and C. tropicalis | MgTEF1p-CAS9-MgTRP1t | pAgTEF1-sgRNA-HDV-ScCYC1t | ADE2 and CPAR2_101060 | To construct an autonomously replicating plasmid for markerless ediing in Candida spp. | Single gene distribution efficiency observed in C. parapsilosis (approximately 80%), C. meta psilosis (100%), C. tropicalis (88–100%) | Lombardi et al. (2019) [67] |
Cryptococcus neoformance | TEF1p-Cas9-SV40NLS-TEF1t | pACT1-HH-gRNA-HDV-TRPt | ADE2 | To demonstrate the first proof of principle study | 70% | Arras et al. (2016) [71] |
C. neoformans | ACT1P-SV40NLS-Cas9-NLS-bGHpAt | pCnU6-GN19-gRNA-6Ts | ADE2 and Tsp2-1 | To develop a system for gene alterations by subsequent complementation and off-target effects reduction | Frequency of gene deletion was over 80%, indel efficiency and HR rates were 40–90% and 20–90%, respectively | Wang et al. (2016) [72] |
C. neoformans | GPD1p–Cas9-GPD1 t | pCnU6-sgRNA-6-Tt | ADE2 | To generate a TRACE system as an cost-effective and efficient strategy for genetic modifications | Up to 90% gene disruption rate | Fan et al. (2018) [73] |
C. neoformans | pTEF-Cas9-FLAG-NLS | ptRNA-sgRNA-NLS | GIB2 | To deliver a preassembled RNP via electroporation to accelerate of gene editing | Approach is sufficient to induce gene modification | Wang P. (2018) [74] |
4.2. Filamentous Fungi
Although filamentous fungi are well-known for producing high-value substances and metabolites including drugs, they have increasingly been problematic by causing life-threatening human infections [75,76,77,78,79,80]. Therefore, exploiting their genome function through applying precise and efficient techniques, thereby preventing the fungal infections, is critical. Regardless of benefit or health risks, genetic tools have not been well developed in filamentous fungi. It has been shown that polyketide synthase (PKS) is a crucial enzyme needed for toxin biosynthesis in filamentous fungi [81] and its disruption yields to engineered fungi with significant reduction in their detrimental effect to its host [82]. As a proof of principle, in a study by Fuller and colleagues, PKS in A. fumigatus was targeted for loss-of-function study using the CRISPR system [83]. They found high editing efficiency (25–53%) and demonstrated that the constitutive expression of Cas9 is not deleterious to A. fumigatus growth and other features. Additionally, Cas9-hph strain was constructed to be used as a universal recipient of sgRNA in CRISPR-based engineering. Since then, to enhance efficiency rates, in-frame integration with or without marker insertion with approximately 95–100% accuracy assisted by microhomology-mediated end joining (MMEJ) has been developed in A. fumigatus [84]. The genetic alteration via the CRISPR/Cas9 system has been effectively developed in A. fumigatus to determine the importance of various genes in Aspergillus [46,47,48]. For instance, the CRISPR has been applied by Umeyama and colleagues to replace cyp51A gene in azole-resistant clinical A. fumigatus isolates [46]. In this study, ribonucleoprotein complex of Cas9/gRNA and donor template have been simultaneously delivered into cells followed by testing azole susceptibility in transformants, which showed increased susceptibility via the replacement of Ser138 by glycine [46]. These studies demonstrated high performance of CRISPR/Cas9 system in Aspergillus research together with diversity in usability of systems components. Recently, a CRISPR-based plasmid free approach (a Cas9 RNP-mediated method) targeted for carB and hmgR2 genes of Mucor circinelloides resulted in stable gene disruption mutants [85]. To investigate molecular pathogenesis mechanisms of Rhizopus delemar, single nucleotide (nt) deletions in two clinical strains FGSC-9543 and CDC-8219 were carried out [86]. Taken together, these data indicate that these approaches are simple and reliable and can be adapted in other filamentous fungi as well. Strategies and applications of CRISPR/Cas9 system in medically important filamentous fungi are shown in Table 2.
Table 2.
Organism | CAS9 Expression Module | GRNA Expression Module | Target Gene (S) | Purpose of Application | Editing Rate and Result | References |
---|---|---|---|---|---|---|
A. fumigatus | p-hph-Ptef1-cas9 | p426-SNR52p-gRNA.CAN1.Y-SUP4t | PKSP | To test CRISPR-CAS9 method in this organism | High gene targeting efficiency reached 25–53% | Fuller et al. (2015) [83] |
A. fumigatus | Gpdap-3xFLAG-NLS-Cas9-NLS-TRPCt | U6-3-gRNA | pksP and cnaA genes | To establish the system for mutagenesis using MMEJ process | Approximately 95–100% rate of mutagenesis obtained | Zhang et al. (2016) [84] |
A. fumigatus | Alt-R-CRISPR-Cas9 components from integrated DNA technologies (IDT) | cr5 = pksP and cr3 = pksP | PKSP | An in vitro assembly of RNP demonstrated to eliminate the strain construction step | Gene deletion efficiency was close to 100% | Al-Abdallah et al. (2017) [48] |
A. fumigatus | Cas9-NLS | T7-sgRNA | CYP51A | To investigate the mechanisms of azole resistance via cyp51A alteration | Site-directed mutagenesis successfully performed using CRISPR-CAS9 system | Umeyama et al. (2018) [46] |
Mucor circinelloides | Alt-R CRISPR-Cas9 tracrRNA | Alt-R CRISPR crRNA | CARB and HMGR2 | To obtain mitotically stable mutants, a plasmid free CRISPR-Cas9 approach demonstrated | Targeting efficiency of NHEJ and HR reach to 100% | Nagy et al. (2017) [85] |
Rhizopus delemar | pmCas9: tRNA-gRNA | pmCas9: tRNA-gRNA | PYRF | For investigating molecular pathogenesis mechanisms, point mutation introduced | Efficiency of 36% to 59% | Bruni et al. (2019) [86] |
5. Conclusions and Future Prospects
Genetic engineering in many pathogenic fungi has been advanced in recent years and smooths the way for successful developments in the field of fungal genetics and molecular biology.
ZFNs and TALENS are useful technologies, as they facilitate researchers to create permanent mutations by introducing double-stranded breaks to activate repair pathways. However, these strategies are expensive and time-consuming to engineer, especially in large scale, high-throughput studies. A major advantage of RNAi is that a gene silencing and actual knockdown of gene expression is very simple. Unlike CRISPRi, RNAi does not target TSSs and also targets RNA transcripts in the cells’ cytoplasm and not genomic DNA in the nucleus [87,88]. However, in contrast to Cas9 and TALE systems, irreversible knockout experiments are not possible using RNAi experiment. In comparison with RNAi, studies show stronger loss-of-function phenotypes with low off-targeting effects when using CRISPRi [88]. Therefore, only from the view point of ease of use in some experiments could RNAi be ahead of CRISPRi-based technologies.
Among the various technologies, CRISPR-based techniques permit a simpler design process, and more affordable and faster execution than engineered nuclease platforms, making them highly favorable engineering tools for industrially important microorganisms with limited availability of genetic tools. The information presented in this review suggests that the CRISPR-Cas9 technique has been successfully established for several human pathogenic fungi.
For generating more than 100 mutated strains, different approaches with edition efficiencies from too low to 100% have been used, and in most cases the application of the technique consisted of a proof of concept of its feasibility. Depending on the efficiency of homologous recombination and fungal intrinsic identity, CRISPR-based genome edition may vary from a simple single gene mutation to a complex multi-gene expression regulation. Regardless of the purpose of the study, efficiency of the system might be improved through targeted change on plasmid or donor DNA [47,48,49,89]. Employment of NHEJ mutant strains was shown to be indispensable for enhancing efficiency of homologous recombination in some studies [69,90]. However, marker-less gene deletion strain construction using transient expression plasmids that can self-replicate only under antibiotic pressure is an advantage [59,91,92,93,94,95,96].
Multiplexing properties of the CRISPR system [97,98,99,100,101,102,103,104,105,106] can accelerate its ability in many aspects in the future. For instance, in development of fungal cell factories for the production of added value metabolites [107] or in development of new antifungal bioactive compounds [108], the system can be an affordable facilitator tool through approaches like genome reduction to overrule unwanted products [109] and constructing sets of deletion mutants over fungal gene interaction networks [110], respectively. A catalytically dead version of Cas9 (dCas9) has been developed by adding two point mutations in Cas9 [52], and as an extension of its application, transcriptional reprogramming [111,112] for regulation of gene expression has been introduced. These approaches might be attractive tools for gene regulation in filamentous fungi that lack components of RNAi machinery as well as in multinucleated fungi. Speed, accuracy, and sensitivity in diagnosis are critical components for cost-effective detection of fungi, subsequent prevention, and treatment of fungal infections [113,114]. Current methods of diagnosis of fungal infections are time consuming and include an expensive process of phenotypic and biochemical approaches. Thus, a demand for modern molecular diagnostic methods like genomic imaging with Cas9 has been increased. Although the CRISPR/Cas9 technique has become an increasingly important tool for several applications in line of fungal research, off-target effect, especially when using multiple sgRNAs can still limit applications of CRISPR-Cas9 system. It is worth noting that CRISPR is not the latest genome manipulation technology. Prime editing is the newest class of known gene editing methods that has been introduced in the field of biotechnology since 2019. Prime editing, which can be used in biological systems, first searches for the points in the gene that need to be modified, then impose the editing effects, without breaking into double stranded DNA at the target points, through base deletion, insertion, and substitutions. The most notable advantage of this method to CRISPR is that it has less off-target effects and is more precise [115,116,117]. This technique is still in its infancy and has not yet been used in pathogenic fungi.
Abbreviations
Ago | Argonaute |
AIDS | acquired immunodeficiency syndrome |
CRISPR | clustered regularly interspaced short palindromic repeats |
CRISPR-Cas9 | clustered regularly interspaced short palindromic repeats associated protein 9 |
Cas9-NLS | cas9 with a nuclear localization signal |
crRNA | CRISPR RNA |
dCas9 | dead version of Cas9 |
DSB | double stranded break |
dsRNA | double-stranded RNA |
HR | homologous recombination |
HDR | homology directed repair |
IDT | integrated DNA technologies |
MIC | minimum inhibitory concentration |
mRNA | messenger RNA |
NHEJ | non-homologous end joining |
NGG | nucleotide- guanine-guanine |
PAM | protospacer adjacent motif |
PKS | polyketide synthase |
REMI | restriction enzyme mediated integration |
RISC | RNA- induced silencing complex |
RVD | repeat variable di-residues |
SAT1-FLP | SAT1 flipper |
siRNA | small interfering RNA |
sgRNA | single guide RNA |
SNP | single nucleotide polymorphism |
TALEN | transcription activator-like effector nucleases |
tracrRNA | trans-activating crRNA |
ZFN | zinc-finger nuclease |
Author Contributions
S.K. and M.T.H. contributed to conceptualization. S.N. and S.H. wrote the first draft. S.K., S.S., J.T., F.K. and M.T.H. contributed to reviewing and revising the manuscript. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding. S.S was supported by a research fund from Intramural Research Program of the National Institutes of Health, Clinical Center, Department of Laboratory Medicine.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors report no conflicts of interest related to this manuscript. The authors alone are responsible for the content and writing of the paper.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Lin X., Alspaugh J.A., Liu H., Harris S. Fungal Morphogenesis. Cold Spring Harb. Perspect. Med. 2014;5:a019679. doi: 10.1101/cshperspect.a019679. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Schmiedel Y., Zimmerli S. Common invasive fungal diseases: An overview of invasive candidiasis, aspergillosis, cryptococcosis and Pneumocystis pneumonia. Swiss Med. Wkly. 2016;146:14281. doi: 10.4414/smw.2016.14281. [DOI] [PubMed] [Google Scholar]
- 3.Ramana K.V., Kandi S.P.V.B., Sharada C.V., Rao R., Mani R., Rao S.D. Invasive Fungal Infections: A Comprehensive Review. Am. J. Infect. Dis. Microbiol. 2013;1:64–69. doi: 10.12691/ajidm-1-4-2. [DOI] [Google Scholar]
- 4.Wang Q., Zhong C., Xiao H. Genetic Engineering of Filamentous Fungi for Efficient Protein Expression and Secretion. Front. Bioeng. Biotechnol. 2020;8:293. doi: 10.3389/fbioe.2020.00293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Hittinger C.T., Alexander W.G. Constructs and Methods for Genome Editing and Genetic Engineering of Fungi and Protists. 9879270. U.S. Patent. 2018 Jan 30;
- 6.Perez-Nadales E., Nogueira M.F.A., Baldin C., Castanheira S., El Ghalid M., Grund E., Lengeler K., Marchegiani E., Mehrotra P.V., Moretti M., et al. Fungal model systems and the elucidation of pathogenicity determinants. Fungal Genet. Biol. 2014;70:42–67. doi: 10.1016/j.fgb.2014.06.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Dudakova A., Spiess B., Tangwattanachuleeporn M., Sasse C., Buchheidt D., Weig M., Groß U., Bader O. Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species. Clin. Microbiol. Rev. 2017;30:1065–1091. doi: 10.1128/CMR.00095-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Gaj T., Sirk S.J., Shui S.-L., Liu J. Genome-Editing Technologies: Principles and Applications. Cold Spring Harb. Perspect. Biol. 2016;8:a023754. doi: 10.1101/cshperspect.a023754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Hilton I.B., Gersbach C.A. Enabling functional genomics with genome engineering. Genome Res. 2015;25:1442–1455. doi: 10.1101/gr.190124.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Chang S.-S., Zhang Z., Liu Y. RNA Interference Pathways in Fungi: Mechanisms and Functions. Annu. Rev. Microbiol. 2012;66:305–323. doi: 10.1146/annurev-micro-092611-150138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Lax C., Tahiri G., Patiño-Medina J.A., Cánovas-Márquez J.T., Pérez-Ruiz J.A., Osorio-Concepción M., Navarro E., Calo S. The Evolutionary Significance of RNAi in the Fungal Kingdom. Int. J. Mol. Sci. 2020;21:9348. doi: 10.3390/ijms21249348. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Mousavi B., Hedayati M.T., Teimoori-Toolabi L., Guillot J., Alizadeh A., Badali H. cyp51A gene silencing using RNA interference in azole-resistant Aspergillus fumigatus. Mycoses. 2015;58:699–706. doi: 10.1111/myc.12417. [DOI] [PubMed] [Google Scholar]
- 13.Martel C.M., Parker J.E., Bader O., Weig M., Gross U., Warrilow A.G.S., Kelly D.E., Kelly S.L. A Clinical Isolate of Candida albicans with Mutations in ERG11 (Encoding Sterol 14α-Demethylase) and ERG5 (Encoding C22 Desaturase) is Cross Resistant to Azoles and Amphotericin B. Antimicrob. Agents Chemother. 2010;54:3578–3583. doi: 10.1128/AAC.00303-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Sanglard D., Ischer F., Parkinson T., Falconer D., Bille J. Candida albicans Mutations in the Ergosterol Biosynthetic Pathway and Resistance to Several Antifungal Agents. Antimicrob. Agents Chemother. 2003;47:2404–2412. doi: 10.1128/AAC.47.8.2404-2412.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Zhou Y., Liao M., Zhu C., Hu Y., Tong T., Peng X., Li M., Feng M., Cheng L., Ren B., et al. ERG3 and ERG11 genes are critical for the pathogenesis of Candida albicans during the oral mucosal infection. Int. J. Oral Sci. 2018;10:1–8. doi: 10.1038/s41368-017-0006-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Chang Z., Yadav V., Lee S.C., Heitman J. Epigenetic mechanisms of drug resistance in fungi. Fungal Genet. Biol. 2019;132:103253. doi: 10.1016/j.fgb.2019.103253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Poças-Fonseca M.J., Cabral C.G., Manfrão-Netto J.H.C. Epigenetic manipulation of filamentous fungi for biotechnological applications: A systematic review. Biotechnol. Lett. 2020;42:885–904. doi: 10.1007/s10529-020-02871-8. [DOI] [PubMed] [Google Scholar]
- 18.Brandão F., Esher S.K., Ost K.S., Pianalto K., Nichols C.B., Fernandes L., Bocca A.L., Poças-Fonseca M.J., Alspaugh J.A. HDAC genes play distinct and redundant roles in Cryptococcus neoformans virulence. Sci. Rep. 2018;8:1–17. doi: 10.1038/s41598-018-21965-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Brandão F.A., Derengowski L.S., Albuquerque P., Nicola A.M., Silva-Pereira I., Poças-Fonseca M.J. Histone deacetylases inhibitors effects on Cryptococcus neoformans major virulence phenotypes. Virulence. 2015;6:618–630. doi: 10.1080/21505594.2015.1038014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Elbashir S.M., Harborth J., Weber K., Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. 2002;26:199–213. doi: 10.1016/S1046-2023(02)00023-3. [DOI] [PubMed] [Google Scholar]
- 21.Martinez J., Patkaniowska A., Elbashir S.M., Harborth J., Hossbach M., Urlaub H., Meyer J., Weber K., VanDenburgh K., Manninga H., et al. Analysis of mammalian gene function using small interfering RNAs. Nucleic Acids Symp. Ser. 2003;3:333. doi: 10.1093/nass/3.1.333. [DOI] [PubMed] [Google Scholar]
- 22.Alic N., Hoddinott M.P., Foley A., Slack C., Piper M.D.W., Partridge L. Detrimental Effects of RNAi: A Cautionary Note on its use in Drosophila Ageing Studies. PLoS ONE. 2012;7:e45367. doi: 10.1371/journal.pone.0045367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Roberts R.J., Murray K. Restriction Endonuclease. CRC Crit. Rev. Biochem. 1976;4:123–164. doi: 10.3109/10409237609105456. [DOI] [PubMed] [Google Scholar]
- 24.Brown D.H., Slobodkin I.V., Kumamoto C.A. Stable transformation and regulated expression of an inducible reporter construct in Candida albicans using restriction enzyme-mediated integration. Mol. Genet. Genom. 1996;251:75–80. doi: 10.1007/bf02174347. [DOI] [PubMed] [Google Scholar]
- 25.Brown J.S., Aufauvre-Brown A., Holden D.W. Insertional mutagenesis of Aspergillus fumigatus. Mol. Genet. Genom. 1998;259:327–335. doi: 10.1007/s004380050819. [DOI] [PubMed] [Google Scholar]
- 26.Warrilow A.G.S., Parker J.E., Price C.L., Nes W.D., Kelly S.L., Kelly D.E. In Vitro Biochemical Study of CYP51-Mediated Azole Resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 2015;59:7771–7778. doi: 10.1128/AAC.01806-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Jiang C., Dong D., Yu B., Cai G., Wang X., Ji Y., Peng Y. Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J. Antimicrob. Chemother. 2012;68:778–785. doi: 10.1093/jac/dks481. [DOI] [PubMed] [Google Scholar]
- 28.Lartigue C., Vashee S., Algire M.A., Chuang R.-Y., Benders G.A., Ma L., Noskov V.N., Denisova E.A., Gibson D.G., Assad-Garcia N., et al. Creating Bacterial Strains from Genomes that Have Been Cloned and Engineered in Yeast. Science. 2009;325:1693–1696. doi: 10.1126/science.1173759. [DOI] [PubMed] [Google Scholar]
- 29.Kim Y.G., Cha J., Chandrasegaran S. Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. USA. 1996;93:1156. doi: 10.1073/pnas.93.3.1156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Urnov F.D., Rebar E.J., Holmes M.C., Zhang H.S., Gregory P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 2010;11:636–646. doi: 10.1038/nrg2842. [DOI] [PubMed] [Google Scholar]
- 31.Carroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011;188:773–782. doi: 10.1534/genetics.111.131433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Joung J.K., Sander J.D. TALENs: A widely applicable technology for targeted genome editing. Nat. Rev. Mol. Cell Biol. 2012;14:49–55. doi: 10.1038/nrm3486. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Gaj T., Gersbach C.A., Barbas C.F. Zfn, Talen and Crispr/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397–405. doi: 10.1016/j.tibtech.2013.04.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., et al. Multiplex Genome Engineering using CRISPR/Cas Systems. Science. 2013;339:819–823. doi: 10.1126/science.1231143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. RNA-Guided Human Genome Engineering via Cas9. Science. 2013;339:823–826. doi: 10.1126/science.1232033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Dicarlo J.E., Norville J.E., Mali P., Rios X., Aach J., Church G.M. Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Res. 2013;41:4336–4343. doi: 10.1093/nar/gkt135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Kennedy E.M., Bassit L.C., Mueller H., Kornepati A.V., Bogerd H.P., Nie T., Chatterjee P., Javanbakht H., Schinazi R.F., Cullen B.R. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology. 2015;476:196–205. doi: 10.1016/j.virol.2014.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Ran F.A., Hsu P.D., Wright J., Agarwala V., Scott D.A., Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 2013;8:2281–2308. doi: 10.1038/nprot.2013.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Li Y., Li S., Wang J., Liu G. CRISPR/Cas Systems towards Next-Generation Biosensing. Trends Biotechnol. 2019;37:730–743. doi: 10.1016/j.tibtech.2018.12.005. [DOI] [PubMed] [Google Scholar]
- 40.Wang J., Lu A., Bei J., Zhao G., Wang J. CRISPR/ddCas12a-based programmable and accurate gene regulation. Cell Discov. 2019;5:15. doi: 10.1038/s41421-019-0085-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Vercoe R.B., Chang J.T., Dy R.L., Taylor C., Gristwood T., Clulow J.S., Richter C., Przybilski R., Pitman A.R., Fineran P.C. Cytotoxic Chromosomal Targeting by CRISPR/Cas Systems Can Reshape Bacterial Genomes and Expel or Remodel Pathogenicity Islands. PLoS Genet. 2013;9:e1003454. doi: 10.1371/journal.pgen.1003454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Farboud B., Jarvis E., Roth T.L., Shin J., Corn J.E., Marson A., Meyer B.J., Patel N.H., Hochstrasser M.L. Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms. J. Vis. Exp. 2018;135:e57350. doi: 10.3791/57350. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Rahimi H., Salehiabar M., Barsbay M., Ghaffarlou M., Kavetskyy T., Sharafi A., Davaran S., Chauhan S.C., Danafar H., Kaboli S., et al. Crispr Systems for COVID-19 Diagnosis. ACS Sensors. 2021 doi: 10.1021/acssensors.0c02312. [DOI] [PubMed] [Google Scholar]
- 44.Sasano Y., Nagasawa K., Kaboli S., Sugiyama M., Harashima S. CRISPR-PCS: A powerful new approach to inducing multiple chromosome splitting in Saccharomyces cerevisiae. Sci. Rep. 2016;6:1–11. doi: 10.1038/srep30278. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Kuivanen J., Wang Y.-M.J., Richard P. Engineering Aspergillus niger for galactaric acid production: Elimination of galactaric acid catabolism by using RNA sequencing and CRISPR/Cas9. Microb. Cell Fact. 2016;15:1–9. doi: 10.1186/s12934-016-0613-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Umeyama T., Hayashi Y., Shimosaka H., Inukai T., Yamagoe S., Takatsuka S., Hoshino Y., Nagi M., Nakamura S., Kamei K., et al. CRISPR/Cas9 Genome Editing to Demonstrate the Contribution of Cyp51A Gly138Ser to Azole Resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 2018;62 doi: 10.1128/AAC.00894-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Gu Y., Gao J., Cao M., Dong C., Lian J., Huang L., Cai J., Xu Z. Construction of a series of episomal plasmids and their application in the development of an efficient CRISPR/Cas9 system in Pichia pastoris. World J. Microbiol. Biotechnol. 2019;35:79. doi: 10.1007/s11274-019-2654-5. [DOI] [PubMed] [Google Scholar]
- 48.Al Abdallah Q., Ge W., Fortwendel J.R. A Simple and Universal System for Gene Manipulation in Aspergillus fumigatus: In Vitro-Assembled Cas9-Guide RNA Ribonucleoproteins Coupled with Microhomology Repair Templates. Msphere. 2017;2:e00446. doi: 10.1128/mSphere.00446-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Gong Z., Karlsson A.J. Translocation of cell-penetrating peptides into Candida fungal pathogens. Protein Sci. 2017;26:1714–1725. doi: 10.1002/pro.3203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Farkhani S.M., Valizadeh A., Karami H., Mohammadi S., Sohrabi N., Badrzadeh F. Cell penetrating peptides: Efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides. 2014;57:78–94. doi: 10.1016/j.peptides.2014.04.015. [DOI] [PubMed] [Google Scholar]
- 51.Idnurm A., Meyer V. The CRISPR revolution in fungal biology and biotechnology, and beyond. Fungal Biol. Biotechnol. 2018;5:19. doi: 10.1186/s40694-018-0064-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science. 2012;337:816–821. doi: 10.1126/science.1225829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Makarova K.S., Koonin E.V. Methods in Molecular Biology. Volume 1311. Springer Science and Business Media; Berlin/Heidelberg, Germany: 2015. Annotation and Classification of CRISPR-Cas Systems; pp. 47–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Horvath P., Barrangou R. CRISPR/Cas the Immune System of Bacteria and Archaea. Science. 2010;327:167–170. doi: 10.1126/science.1179555. [DOI] [PubMed] [Google Scholar]
- 55.Jiang F., Doudna J.A. CRISPR–Cas9 Structures and Mechanisms. Annu. Rev. Biophys. 2017;46:505–529. doi: 10.1146/annurev-biophys-062215-010822. [DOI] [PubMed] [Google Scholar]
- 56.Brandsma I., Van Gent D.C. Pathway choice in DNA double strand break repair: Observations of a balancing act. Genome Integr. 2012;3:1–10. doi: 10.1186/2041-9414-3-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Vyas V.K., Barrasa M.I., Fink G.R. A Candida albicans CRISPR system permits genetic engineering of essential genes and gene families. Sci. Adv. 2015;1:e1500248. doi: 10.1126/sciadv.1500248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Nguyen N., Quail M.M.F., Hernday A.D. An Efficient, Rapid and Recyclable System for CRISPR-Mediated Genome Editing in Candida albicans. Msphere. 2017;2:e00149. doi: 10.1128/mSphereDirect.00149-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Min K., Ichikawa Y., Woolford C.A., Mitchell A.P. Candida albicans Gene Deletion with a Transient CRISPR-Cas9 System. Msphere. 2016;1:e00130. doi: 10.1128/mSphere.00130-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Min K., Biermann A., Hogan D.A., Konopka J.B. Genetic Analysis ofNDT80Family Transcription Factors in Candida albicans using new CRISPR-Cas9 Approaches. Msphere. 2018;3:e00545. doi: 10.1128/mSphere.00545-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Enkler L., Richer D., Marchand A.L., Ferrandon D., Jossinet F. Genome engineering in the yeast pathogen Candida glabrata using the CRISPR-Cas9 system. Sci. Rep. 2016;6:35766. doi: 10.1038/srep35766. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Cen Y., Timmermans B., Souffriau B., Thevelein J.M., Van Dijck P. Comparison of genome engineering using the CRISPR-Cas9 system in C. glabrata wild-type and lig4 strains. Fungal Genet. Biol. 2017;107:44–50. doi: 10.1016/j.fgb.2017.08.004. [DOI] [PubMed] [Google Scholar]
- 63.Shapiro R.S., Chavez A., Porter C.B.M., Hamblin M., Kaas C.S., Dicarlo J.E., Zeng G., Xu X., Revtovich A.V., Kirienko N.V., et al. A CRISPR-Cas9-based gene drive platform for genetic interaction analysis in Candida albicans. Nat. Microbiol. 2018;3:73–82. doi: 10.1038/s41564-017-0043-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Ng H., Dean N. Dramatic Improvement of CRISPR/Cas9 Editing in Candida albicans by Increased Single Guide RNA Expression. Msphere. 2017;2 doi: 10.1128/mSphere.00385-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Halder V., Porter C.B.M., Chavez A., Shapiro R.S. Design, execution and analysis of CRISPR-Cas9-based deletions and genetic interaction networks in the fungal pathogen Candida albicans. Nat. Protoc. 2019;14:955–975. doi: 10.1038/s41596-018-0122-6. [DOI] [PubMed] [Google Scholar]
- 66.Lombardi L., Turner S.A., Zhao F., Butler G. Gene editing in clinical isolates of Candida parapsilosis using CRISPR/Cas9. Sci. Rep. 2017;7:1–11. doi: 10.1038/s41598-017-08500-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Lombardi L., Oliveira-Pacheco J., Butler G. Plasmid-Based CRISPR-Cas9 Gene Editing in Multiple Candida Species. Msphere. 2019;4:e00125. doi: 10.1128/mSphere.00125-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Wensing L., Sharma J., Uthayakumar D., Proteau Y., Chavez A., Shapiro R.S. A CRISPR Interference Platform for Efficient Genetic Repression in Candida albicans. Msphere. 2019;4:e00002. doi: 10.1128/mSphere.00002-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Elhariri M., Hamza D., Elhelw R., Refai M. Eucalyptus Tree: A Potential Source of Cryptococcus neoformansin Egyptian Environment. Int. J. Microbiol. 2016;2016:1–5. doi: 10.1155/2016/4080725. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Andreou M., Cogliati M., Kolonitsiou F., Stroumpos C., Stamouli V., Ravazoula P., Siagris D., Papadogeorgaki H., Christofidou M., Lekkou A. Cryptococcus gattii infection in an immunocompetent host in Greece. Med Mycol. Case Rep. 2020;27:1–3. doi: 10.1016/j.mmcr.2019.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Arras S.D.M., Chua S.M.H., Wizrah M.S.I., Faint J.A., Yap A.S., Fraser J.A. Targeted Genome Editing via CRISPR in the Pathogen Cryptococcus neoformans. PLoS ONE. 2016;11:e0164322. doi: 10.1371/journal.pone.0164322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Wang Y., Wei D., Zhu X., Pan J., Zhang P., Huo L., Zhu X. A ‘suicide’ CRISPR-Cas9 system to promote gene deletion and restoration by electroporation in Cryptococcus neoformans. Sci. Rep. 2016;6:31145. doi: 10.1038/srep31145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Fan Y., Lin X. Multiple Applications of a Transient CRISPR-Cas9 Coupled with Electroporation (TRACE) System in the Cryptococcus neoformans Species Complex. Genetics. 2018;208:1357–1372. doi: 10.1534/genetics.117.300656. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Wang P. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species. Msphere. 2018;3:e00208. doi: 10.1128/mSphereDirect.00208-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Pagano L., Girmenia C., Mele L., Ricci P.E., Tosti M., Nosari A., Buelli M., Picardi M., Allione B., Corvatta L., et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematology. 2001;86:862–870. [PubMed] [Google Scholar]
- 76.Pihet M., Carrere J., Cimon B., Chabasse D., Delhaes L., Symoens F., Bouchara J.-P. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis—A review. Med. Mycol. 2009;47:387–397. doi: 10.1080/13693780802609604. [DOI] [PubMed] [Google Scholar]
- 77.Slavin M., Van Hal S., Sorrell T., Lee A., Marriott D., Daveson K., Kennedy K., Hajkowicz K., Halliday C., Athan E., et al. Invasive infections due to filamentous fungi other than Aspergillus: Epidemiology and determinants of mortality. Clin. Microbiol. Infect. 2015;21 doi: 10.1016/j.cmi.2014.12.021. [DOI] [PubMed] [Google Scholar]
- 78.Egbuta M.A., Mwanza M., Babalola O.O. Health Risks Associated with Exposure to Filamentous Fungi. Int. J. Environ. Res. Public Health. 2017;14:719. doi: 10.3390/ijerph14070719. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Lamoth F., Calandra T. Let’s add invasive aspergillosis to the list of influenza complications. Lancet Respir. Med. 2018;6:733–735. doi: 10.1016/S2213-2600(18)30332-1. [DOI] [PubMed] [Google Scholar]
- 80.Lim S.-Y., Son Y.-E., Lee D.-H., Eom T.-J., Kim M.-J., Park H.-S. Function of crzA in Fungal Development and Aflatoxin Production in Aspergillus flavus. Toxins. 2019;11:567. doi: 10.3390/toxins11100567. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Langfelder K., Jahn B., Gehringer H., Schmidt A., Wanner G., Brakhage A.A. Identification of a polyketide synthase gene (pksP) of Aspergillus fumigatus involved in conidial pigment biosynthesis and virulence. Med. Microbiol. Immunol. 1998;187:79–89. doi: 10.1007/s004300050077. [DOI] [PubMed] [Google Scholar]
- 82.Yang G., Rose M.S., Turgeon B.G., Yoder O.C. A polyketide synthase is required for fungal virulence and production of the polyketide T-toxin. Plant Cell. 1996;8:2139–2150. doi: 10.1105/tpc.8.11.2139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Fuller K.K., Chen S., Loros J.J., Dunlap J.C. Development of the CRISPR/Cas9 System for Targeted Gene Disruption in Aspergillus fumigatus. Eukaryot. Cell. 2015;14:1073–1080. doi: 10.1128/EC.00107-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Zhang C., Meng X., Wei X., Lu L. Highly efficient CRISPR mutagenesis by microhomology-mediated end joining in Aspergillus fumigatus. Fungal Genet. Biol. 2016;86:47–57. doi: 10.1016/j.fgb.2015.12.007. [DOI] [PubMed] [Google Scholar]
- 85.Nagy G., Szebenyi C., Csernetics A., Vaz A.G., Toth E.J., Vagvolgyi C., Papp T. Development of a plasmid free CRISPR-Cas9 system for the genetic modification of Mucor circinelloides. Sci. Rep. 2017;7:1–10. doi: 10.1038/s41598-017-17118-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Bruni G.O., Zhong K., Lee S.C., Wang P. Crispr-Cas9 induces point mutation in the mucormycosis fungus Rhizopus delemar. Fungal Genet. Biol. 2019;124:1–7. doi: 10.1016/j.fgb.2018.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Agrawal N., Dasaradhi P.V., Mohmmed A., Malhotra P., Bhatnagar R.K., Mukherjee S.K. RNA interference: Biology, mechanism, and applications. Microbiol. Mol. Biol. Rev. 2003;67:657–685. doi: 10.1128/MMBR.67.4.657-685.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Boettcher M., McManus M.T. Choosing the Right Tool for the Job: RNAi, TALEN or CRISPR. Mol. Cell. 2015;58:575–585. doi: 10.1016/j.molcel.2015.04.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Zheng X., Zheng P., Zhang K., Cairns T.C., Meyer V., Sun J., Ma Y. 5S rRNA Promoter for Guide RNA Expression Enabled Highly Efficient CRISPR/Cas9 Genome Editing in Aspergillus niger. ACS Synth. Biol. 2019;8:1568–1574. doi: 10.1021/acssynbio.7b00456. [DOI] [PubMed] [Google Scholar]
- 90.Weninger A., Fischer J.E., Raschmanová H., Kniely C., Vogl T., Glieder A. Expanding the CRISPR/Cas9 toolkit for Pichia pastoris with efficient donor integration and alternative resistance markers. J. Cell. Biochem. 2018;119:3183–3198. doi: 10.1002/jcb.26474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Nødvig C.S., Nielsen J.B., Kogle M.E., Mortensen U.H. A CRISPR-Cas9 System for Genetic Engineering of Filamentous Fungi. PLoS ONE. 2015;10:e0133085. doi: 10.1371/journal.pone.0133085. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Katayama T., Tanaka Y., Okabe T., Nakamura H., Fujii W., Kitamoto K., Maruyama J.-I. Development of a genome editing technique using the CRISPR/Cas9 system in the industrial filamentous fungus Aspergillus oryzae. Biotechnol. Lett. 2016;38:637–642. doi: 10.1007/s10529-015-2015-x. [DOI] [PubMed] [Google Scholar]
- 93.Weyda I., Yang L., Vang J., Ahring B.K., Lübeck M., Lübeck P.S. A comparison of Agrobacterium-mediated transformation and protoplast-mediated transformation with CRISPR-Cas9 and bipartite gene targeting substrates, as effective gene targeting tools for Aspergillus carbonarius. J. Microbiol. Methods. 2017;135:26–34. doi: 10.1016/j.mimet.2017.01.015. [DOI] [PubMed] [Google Scholar]
- 94.Wang Q., Cobine P.A., Coleman J.J. Efficient genome editing in Fusarium oxysporum based on CRISPR/Cas9 ribonucleoprotein complexes. Fungal Genet. Biol. 2018;117:21–29. doi: 10.1016/j.fgb.2018.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Wenderoth M., Pinecker C., Voß B., Fischer R. Establishment of CRISPR/Cas9 in Alternaria alternata. Fungal Genet. Biol. 2017;101:55–60. doi: 10.1016/j.fgb.2017.03.001. [DOI] [PubMed] [Google Scholar]
- 96.Schuster M., Schweizer G., Reissmann S., Kahmann R. Genome editing in Ustilago maydis using the CRISPR-Cas system. Fungal Genet. Biol. 2016;89:3–9. doi: 10.1016/j.fgb.2015.09.001. [DOI] [PubMed] [Google Scholar]
- 97.Zalatan J.G., Lee M.E., Almeida R., Gilbert L.A., Whitehead E.H., La Russa M., Tsai J.C., Weissman J.S., Dueber J.E., Qi L.S., et al. Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds. Cell. 2015;160:339–350. doi: 10.1016/j.cell.2014.11.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Shi S., Liang Y., Zhang M.M., Ang E.L., Zhao H. A highly efficient single-step, markerless strategy for multi-copy chromosomal integration of large biochemical pathways in Saccharomyces cerevisiae. Metab. Eng. 2016;33:19–27. doi: 10.1016/j.ymben.2015.10.011. [DOI] [PubMed] [Google Scholar]
- 99.Zhang J.-L., Peng Y.-Z., Liu D., Liu H., Cao Y.-X., Li B.-Z., Li C., Yuan Y.-J. Gene repression via multiplex gRNA strategy in Y. lipolytica. Microb. Cell Fact. 2018;17:1–13. doi: 10.1186/s12934-018-0909-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100.Liu R., Chen L., Jiang Y., Zhou Z., Zou G. Efficient genome editing in filamentous fungus Trichoderma reesei using the CRISPR/Cas9 system. Cell Discov. 2015;1:15007. doi: 10.1038/celldisc.2015.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Katayama T., Nakamura H., Zhang Y., Pascal A., Fujii W., Maruyama J.-I. Forced Recycling of an AMA1-Based Genome-Editing Plasmid Allows for Efficient Multiple Gene Deletion/Integration in the Industrial Filamentous Fungus Aspergillus oryzae. Appl. Environ. Microbiol. 2018;85:e01896. doi: 10.1128/AEM.01896-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Ronda C., Maury J., Jakočiunas T., Jacobsen S.A.B., Germann S.M., Harrison S.J.A., Borodina I., Keasling J.D., Jensen M.K., Nielsen A.T. CrEdit: CRISPR mediated multi-loci gene integration in Saccharomyces cerevisiae. Microb. Cell Fact. 2015;14:1–11. doi: 10.1186/s12934-015-0288-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Jakočiūnas T., Jensen M.K., Keasling J.D. CRISPR/Cas9 advances engineering of microbial cell factories. Metab. Eng. 2016;34:44–59. doi: 10.1016/j.ymben.2015.12.003. [DOI] [PubMed] [Google Scholar]
- 104.Adiego-Pérez B., Randazzo P., Daran J.M., Verwaal R.A., Roubos J., Daran-Lapujade P., Van Der Oost J. Multiplex genome editing of microorganisms using CRISPR-Cas. FEMS Microbiol. Lett. 2019;366:86. doi: 10.1093/femsle/fnz086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Ozaki A., Konishi R., Otomo C., Kishida M., Takayama S., Matsumoto T., Tanaka T., Kondo A. Metabolic engineering of Schizosaccharomyces pombe via CRISPR-Cas9 genome editing for lactic acid production from glucose and cellobiose. Metab. Eng. Commun. 2017;5:60–67. doi: 10.1016/j.meteno.2017.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Lian J., Bao Z., Hu S., Zhao H. Engineered CRISPR/Cas9 system for multiplex genome engineering of polyploid industrial yeast strains. Biotechnol. Bioeng. 2018;115:1630–1635. doi: 10.1002/bit.26569. [DOI] [PubMed] [Google Scholar]
- 107.Nielsen J.C. Development of fungal cell factories for the production of secondary metabolites: Linking genomics and metabolism. Synth. Syst. Biotechnol. 2017;2:5–12. doi: 10.1016/j.synbio.2017.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Calderone R., Sun N., Gay-Andrieu F., Groutas W.C., Weerawarna P.M., Prasad S., Alex D., Li D. Antifungal drug discovery: The process and outcomes. Futur. Microbiol. 2014;9:791–805. doi: 10.2217/fmb.14.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Hara S., Jin F.J., Takahashi T., Koyama Y. A further study on chromosome minimization by protoplast fusion in Aspergillus oryzae. Mol. Genet. Genom. 2011;287:177–187. doi: 10.1007/s00438-011-0669-1. [DOI] [PubMed] [Google Scholar]
- 110.Roemer T., Boone C.W. Systems-level antimicrobial drug and drug synergy discovery. Nat. Chem. Biol. 2013;9:222–231. doi: 10.1038/nchembio.1205. [DOI] [PubMed] [Google Scholar]
- 111.Qi L.S., Larson M.H., Gilbert L.A., Doudna J.A., Weissman J.S., Arkin A.P., Lim W.A. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. Cell. 2013;152:1173–1183. doi: 10.1016/j.cell.2013.02.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Kang J.G., Park J.S., Ko J.-H., Kim Y.-S. Regulation of gene expression by altered promoter methylation using a CRISPR/Cas9-mediated epigenetic editing system. Sci. Rep. 2019;9:1–12. doi: 10.1038/s41598-019-48130-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Kozel T.R., Wickes B. Fungal Diagnostics. Cold Spring Harb. Perspect. Med. 2014;4:a019299. doi: 10.1101/cshperspect.a019299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Wickes B.L., Wiederhold N.P. Molecular diagnostics in medical mycology. Nat. Commun. 2018;9:5135. doi: 10.1038/s41467-018-07556-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Matsoukas I.G. Prime Editing: Genome Editing for Rare Genetic Diseases without Double-Strand Breaks or Donor DNA. Front. Genet. 2020;11:528. doi: 10.3389/fgene.2020.00528. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116.Anzalone A.V., Randolph P.B., Davis J.R., Sousa A.A., Koblan L.W., Levy J.M., Chen P.J., Wilson C., Newby G.A., Raguram A., et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nat. Cell Biol. 2019;576:149–157. doi: 10.1038/s41586-019-1711-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117.Abdullah, Jiang Z., Hong X., Zhang S., Yao R., Xiao Y. CRISPR base editing and prime editing: DSB and template-free editing systems for bacteria and plants. Synth. Syst. Biotechnol. 2020;5:277–292. doi: 10.1016/j.synbio.2020.08.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.